A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Complete Title: SC-2032 A PHASE 1B/2, OPEN-LABEL, SINGLE ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF JCAR017 IN PEDIATRIC SUBJECTS WITH RELAPSED/REFRACTORY B-ALL AND B-NHL

Trial Phase: I/II

Investigator: Rebecca Gardner

This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged = 25 years with CD19+ r/r B-ALL and B-NHL. Phase 1 will identify a recommended Phase 2 dose (RP2D). Phase 2 will evaluate the efficacy of JCAR017 RP2D in the following three disease cohorts: Cohort 1 (r/r B-ALL), Cohort 2 (MRD+ B-ALL) and Cohort 3 (r/r B-NHL, [DLBCL, BL, or PMBCL]). A Simon`s Optimal two-stage study design will be applied to Cohort 1 and 2 in Phase 2.

Keywords:

Lymphoma, Non-Hodgkin (NHL)
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.